Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Deferred Revenue (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Current Deferred Revenue for 11 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 64.72% to $7.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.3 million, a 64.72% decrease, with the full-year FY2025 number at $7.3 million, down 64.72% from a year prior.
  • Current Deferred Revenue was $7.3 million for Q4 2025 at Intellia Therapeutics, down from $12.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $127.2 million in Q4 2021 to a low of $7.3 million in Q4 2025.
  • A 5-year average of $52.2 million and a median of $49.2 million in 2023 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 431.33% in 2021; the steepest drop was 77.61% in 2021.
  • Intellia Therapeutics' Current Deferred Revenue stood at $127.2 million in 2021, then crashed by 49.88% to $63.8 million in 2022, then decreased by 4.36% to $61.0 million in 2023, then plummeted by 66.13% to $20.7 million in 2024, then crashed by 64.72% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Current Deferred Revenue are $7.3 million (Q4 2025), $12.2 million (Q3 2025), and $29.7 million (Q2 2025).